Tag: Pharmasyntez

Pharmasyntez Receives Azerbaijan GMP Certificate and Summarizes 2025 Production Results

The press service of the Pharmasyntez Group has announced the successful completion of an audit by the regulatory authority...

Pharmasyntez to launch the first innovative Russian medication to treat blood cancer (CML)

Vamotinib is about to be registered and put into civil circulation by Pharmasyntez, a Russian pharmaceutical company that aims to provide Russian patients with access to new and innovative medications.

Pharmasyntez starts construction of new parenteral nutrition plant in Ussuriysk

The Pharmasyntez Group of companies is going to launch the parenteral (intravenous) nutrition department in Primorye. At a meeting with...

Pharmasyntez to continue producing anti-COVID-19 drug remdesivir without patent for a year

The Russian government on December 30, 2021 approved the extension for one year of a decree originally issued last...

Pharmasyntez-Nord JSC starts manufacturing the Sputnik Light vaccine developed by Gamaleya Research Center

Investments in the vaccine production are over 2 billion rubles. The production capacity is about 4 million vaccine doses per...

INN is assigned to PF-114

PF-114, an original drug product, was given the INN of Vamotinib by the World Health Organization at the 73d...

“Russian Big Pharma must do a 180 degree turn in its way of thinking” Vikram Punia says

A plenary session where Denis Manturov, Minister of Industry and Trade, and Mikhail Murashko, Minister of Health, participated focused...

Remdeform is included into all COVID-19 treatment regimens

Remdesivir (trade name: Remdeform, MA No. ЛП-006505 of October 14, 2020г) has been included into all in-hospital treatment regimens...

Honorary guests of the Tyumen Oil and Gas Forum visited the hormonal plant of Pharmasyntez-Tyumen prepared for launch

On September 15, the Pharmasyntez-Tyumen hormonal plant under construction in Tyumen was visited by Yuri Borisov, Deputy Prime Minister...

The launch of R&D centre at BratskChemSyntez LLC

The R&D centre is tasked to optimise its substance manufacturing process and develop new unique molecules. The complex has modern...

BratskChemSyntez and Reshetnev Siberian State University developed a training program for synthesis operators

The plant technologists and University teachers took part in the development. It will give a deeper understanding of the...

Russian ministers visit Pharmasintez production site

In 2020 the share of the Pharmasyntez Group of Companies in the hospital procurements segment reached 7.3% in terms of volume.